N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
N/A N=66 Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
Coronary Artery Disease
Primary: Chest Tube Losses — 726; 781 millilters — p=<0.1
Phase 4 N=314 Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
Phase 2 N=48 Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?
Clopidogrel
Primary: Bleeding-related Re-hospitalization — 1; 1 participants
N/A N=1,424 Transfusion Trigger After Operations in High Cardiac Risk Patients
Myocardial Infarction · Coronary Revascularization · Acute Renal Failure
Primary: A Composite Endpoint of All-cause Post-randomization Mortality, Myocardial Infarction (MI), Coronary Revascularization, Acute Renal Failure, or Post-randomization…
Phase 4 N=750 The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients
Blood Loss · Tranexamic Acid · Cardiac Surgery
Primary: Postoperative Blood Loss — 290; 300; 290 ml
N/A N=30 Protamine in Cardiac Surgery and Haemostasis
Bleeding · Hemorrhage
Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds
N/A N=100 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
Blood Coagulation Disorders
Primary: Amount of Chest Catheter Drainage 24 Hours Postoperatively — 766; 626 mL
Phase 2 N=242 Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused — 1223.2; 623.5 mL — p=0.001
Phase 3 N=114 Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Bleeding
Primary: Chest Tube Drainage — 200; 225; 375; 400 mL
N/A N=57 Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery
Coronary Artery Bypass Grafting
Primary: Ease of Use — 4; 1 units on a scale
Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery
Coronary Artery Disease
Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493
Phase 4 N=955 Prospective Trial of Tranexamic Acid in Cardiac Surgery
C.Surgical Procedure; Cardiac
Primary: Postoperative Blood Loss — 520; 490; 450 ml
N/A N=722 Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
Anemia
Primary: A Composite of In-hospital Postoperative Morbidity and Mortality — 59; 68 Participants
Phase 4 N=46 Platelet Transfusion During Neonatal Open Heart Surgery
Cardiac Disease · Cardiac Surgery · Cardiopulmonary Bypass
Primary: Amount of Blood Products Transfused — 58; 103 milliliter per kilogram (mL/kg)
Phase 4 N=97 Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
Bleeding · Surgical Blood Loss
Primary: Median Volume of Mediastinal Fluid Collected From Participants — 500; 540 mL
N/A N=192 Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery
Coronary Artery Disease · Coronary Artery Bypass · Erythrocyte Transfusion
Primary: Mean Number of Packed Red Cells Units Transfused During Hospital Stay — 1.13; 1.91 packed red cells units — p=<0.05
N/A N=52 Hemosonics- VCU Cardiac Surgery Clinical Study
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
Phase 4 N=106 PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
Bleeding · Blood Loss, Surgical · Cardiovascular Surgical Procedures
Primary: Chest Tube Output — 1022; 937 mL — p=0.84
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
N/A N=68 Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Phase 4 N=72 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Heart Failure
Primary: Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant — 12; 15 Participants
Phase 3 N=420 Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
Bleeding Cardiac Surgery Patients
Primary: Number of Patients Requiring Additional Hemostatic Intervention — 166; 125; 47; 82 Participants — p=<0.0001
Phase 2 N=60 Transfusion Strategies in Pediatric Cardiothoracic Surgery
Congenital Heart Disease
Primary: Mean Arterial Lactate Level — 1.4; 1.4 mmol/L
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
Phase 2 N=276 A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused at 12 Hours Post Surgery — 401.9; 383.1; 410.3; 377.6 mL — p=0.474
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units